JP2019501226A5 - - Google Patents

Info

Publication number

JP2019501226A5

JP2019501226A5 JP2018555315A JP2018555315A JP2019501226A5 JP 2019501226 A5 JP2019501226 A5 JP 2019501226A5 JP 2018555315 A JP2018555315 A JP 2018555315A JP 2018555315 A JP2018555315 A JP 2018555315A JP 2019501226 A5 JP2019501226 A5 JP 2019501226A5

Authority

JP

Japan

Prior art keywords

manganese

active agent

individual

pharmaceutically acceptable

acceptable salt

Prior art date

2017-01-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000013543 active substance Substances 0.000 claims 29
• 239000003814 drug Substances 0.000 claims 25
• 150000003839 salts Chemical class 0.000 claims 19
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 15
• 229910052748 manganese Inorganic materials 0.000 claims 15
• 239000011572 manganese Substances 0.000 claims 15
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 14
• 229960004308 acetylcysteine Drugs 0.000 claims 14
• 239000000203 mixture Substances 0.000 claims 14
• SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 claims 10
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 10
• 239000012190 activator Substances 0.000 claims 9
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 8
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 6
• -1 DPDP compound Chemical class 0.000 claims 6
• 229910052791 calcium Inorganic materials 0.000 claims 6
• 239000011575 calcium Substances 0.000 claims 6
• UMRUNOIJZLCTGG-UHFFFAOYSA-N calcium;manganese Chemical compound [Ca+2].[Mn].[Mn].[Mn].[Mn] UMRUNOIJZLCTGG-UHFFFAOYSA-N 0.000 claims 6
• 150000001875 compounds Chemical class 0.000 claims 6
• 150000004696 coordination complex Chemical class 0.000 claims 6
• 208000007788 Acute Liver Failure Diseases 0.000 claims 5
• 206010000804 Acute hepatic failure Diseases 0.000 claims 5
• 108010024636 Glutathione Proteins 0.000 claims 5
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 5
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 5
• 231100000836 acute liver failure Toxicity 0.000 claims 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
• 235000018417 cysteine Nutrition 0.000 claims 5
• 229960003180 glutathione Drugs 0.000 claims 5
• HGZODADXHUPMQO-UHFFFAOYSA-N 4-[(2-aminoethylamino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound Cc1ncc(CO)c(CNCCN)c1O HGZODADXHUPMQO-UHFFFAOYSA-N 0.000 claims 4
• JFVHALAXWREODT-UHFFFAOYSA-N C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] Chemical compound C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] JFVHALAXWREODT-UHFFFAOYSA-N 0.000 claims 4
• 229960005489 paracetamol Drugs 0.000 claims 4
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 4
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 4
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 4
• 229960001327 pyridoxal phosphate Drugs 0.000 claims 4
• 239000013589 supplement Substances 0.000 claims 4
• 150000001408 amides Chemical class 0.000 claims 3
• UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 2
• 206010019851 Hepatotoxicity Diseases 0.000 claims 2
• 238000009472 formulation Methods 0.000 claims 2
• 231100000304 hepatotoxicity Toxicity 0.000 claims 2
• 230000007686 hepatotoxicity Effects 0.000 claims 2
• 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
• 208000033626 Renal failure acute Diseases 0.000 claims 1
• 201000011040 acute kidney failure Diseases 0.000 claims 1
• 208000012998 acute renal failure Diseases 0.000 claims 1
• 239000000090 biomarker Substances 0.000 claims 1
• 239000006185 dispersion Substances 0.000 claims 1
• 230000001747 exhibiting effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 230000036542 oxidative stress Effects 0.000 claims 1
• QAOJLUYEMFXJGX-UHFFFAOYSA-D tetracalcium [4-[[carboxymethyl-[2-[carboxymethyl-[[3-hydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]-2-methylpyridin-4-yl]methyl]amino]ethyl]amino]methyl]-5-hydroxy-6-methylpyridin-3-yl]methyl hydrogen phosphate manganese(2+) Chemical compound [Ca++].[Ca++].[Ca++].[Ca++].[Mn++].Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O QAOJLUYEMFXJGX-UHFFFAOYSA-D 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1